Cas no 174006-70-3 (2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-4-carbaldehyde)

2-[4-(Trifluoromethyl)phenyl]-1,3-thiazole-4-carbaldehyde is a versatile heterocyclic aldehyde featuring a thiazole core substituted with a 4-(trifluoromethyl)phenyl group at the 2-position and a formyl group at the 4-position. The trifluoromethyl group enhances its electron-withdrawing properties, making it valuable in organic synthesis, particularly in the construction of pharmacophores and agrochemical intermediates. The aldehyde functionality allows for further derivatization via condensation or nucleophilic addition reactions. Its structural features contribute to high reactivity and selectivity in cross-coupling and cyclization reactions. This compound is useful in medicinal chemistry for the development of bioactive molecules due to its ability to modulate electronic and steric properties in target structures.
2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-4-carbaldehyde structure
174006-70-3 structure
Product Name:2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-4-carbaldehyde
CAS No:174006-70-3
MF:C11H6F3NOS
MW:257.23165178299
MDL:MFCD07772870
CID:98379
PubChem ID:7164656
Update Time:2025-06-09

2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-4-carbaldehyde Chemical and Physical Properties

Names and Identifiers

    • 2-(4-(Trifluoromethyl)phenyl)thiazole-4-carbaldehyde
    • 2-[4-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOLE-4-CARBALDEHYDE
    • AC1OGC7X
    • AC1Q4J2B
    • AG-B-88540
    • CTK0G9424
    • MolPort-000-143-364
    • SBB101853
    • 2-[4-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOLE-4-CARBOXALDEHYDE
    • 4-Formyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole, 4-(4-Formyl-1,3-thiazol-2-yl)benzotrifluoride
    • J-010960
    • 2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-4-carbaldehyde, AldrichCPR
    • 2-[4-(Trifluoromethyl)phenyl]thiazole-4-carbaldehyde
    • FT-0752356
    • Z728141552
    • YPZISSVPSMFGDW-UHFFFAOYSA-N
    • AB01328618-02
    • DTXSID60428221
    • A811594
    • F87177
    • NCGC00333373-01
    • CS-0216602
    • AKOS010225664
    • AS-9237
    • MFCD07772870
    • EN300-52184
    • SCHEMBL2089805
    • 4-Thiazolecarboxaldehyde, 2-[4-(trifluoromethyl)phenyl]-
    • 174006-70-3
    • 2-[4-(Trifluoromethyl)phenyl]-1,3-thiazole-4-carboxaldehyde97%
    • 2-[4-(Trifluoromethyl)phenyl]-1,3-thiazole-4-carboxaldehyde 97%
    • STL451489
    • DB-064930
    • 2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-4-carbaldehyde
    • MDL: MFCD07772870
    • Inchi: 1S/C11H6F3NOS/c12-11(13,14)8-3-1-7(2-4-8)10-15-9(5-16)6-17-10/h1-6H
    • InChI Key: YPZISSVPSMFGDW-UHFFFAOYSA-N
    • SMILES: S1C=C(C=O)N=C1C1C=CC(C(F)(F)F)=CC=1

Computed Properties

  • Exact Mass: 257.01200
  • Monoisotopic Mass: 257.01221947g/mol
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 0
  • Hydrogen Bond Acceptor Count: 2
  • Heavy Atom Count: 17
  • Rotatable Bond Count: 3
  • Complexity: 276
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 0
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • XLogP3: 3.3
  • Topological Polar Surface Area: 58.2?2

Experimental Properties

  • Melting Point: 103-105
  • PSA: 58.20000
  • LogP: 3.64140

2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-4-carbaldehyde Security Information

2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-4-carbaldehyde Customs Data

  • HS CODE:2934100090
  • Customs Data:

    China Customs Code:

    2934100090

    Overview:

    2934100090. Compounds that structurally contain a non fused thiazole ring(Whether hydrogenated or not). VAT:17.0%. Tax refund rate:9.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%

    Declaration elements:

    Product Name, component content, use to

    Summary:

    2934100090 other compounds containing an unfused thiazole ring (whether or not hydrogenated) in the structure VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:20.0%

2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-4-carbaldehyde Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
Chemenu
CM127837-1g
2-(4-(trifluoromethyl)phenyl)thiazole-4-carbaldehyde
174006-70-3 95%
1g
$317 2021-08-05
TRC
T901353-25mg
2-[4-(Trifluoromethyl)Phenyl]-1,3-Thiazole-4-Carbaldehyde
174006-70-3
25mg
$ 50.00 2022-06-02
TRC
T901353-50mg
2-[4-(Trifluoromethyl)Phenyl]-1,3-Thiazole-4-Carbaldehyde
174006-70-3
50mg
$ 70.00 2022-06-02
TRC
T901353-250mg
2-[4-(Trifluoromethyl)Phenyl]-1,3-Thiazole-4-Carbaldehyde
174006-70-3
250mg
$ 250.00 2022-06-02
Chemenu
CM127837-1g
2-(4-(trifluoromethyl)phenyl)thiazole-4-carbaldehyde
174006-70-3 95%
1g
$202 2023-02-17
Apollo Scientific
PC9656-1g
2-[4-(Trifluoromethyl)phenyl]-1,3-thiazole-4-carboxaldehyde
174006-70-3
1g
£130.00 2025-02-22
abcr
AB224916-1 g
2-[4-(Trifluoromethyl)phenyl]-1,3-thiazole-4-carbaldehyde, 95%; .
174006-70-3 95%
1g
€221.00 2023-06-22
Alichem
A059004403-1g
2-(4-(Trifluoromethyl)phenyl)thiazole-4-carbaldehyde
174006-70-3 95%
1g
$335.61 2022-04-02
Enamine
EN300-52184-0.05g
2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-4-carbaldehyde
174006-70-3 95.0%
0.05g
$21.0 2025-03-15
Enamine
EN300-52184-0.1g
2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-4-carbaldehyde
174006-70-3 95.0%
0.1g
$30.0 2025-03-15

Additional information on 2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-4-carbaldehyde

Introduction to 2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-4-carbaldehyde (CAS No. 174006-70-3)

2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-4-carbaldehyde, identified by its Chemical Abstracts Service (CAS) number 174006-70-3, is a structurally intriguing heterocyclic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the thiazole class, a scaffold widely recognized for its broad spectrum of biological activities and therapeutic potential. The presence of a trifluoromethyl group at the para position of the phenyl ring and the aldehyde functionality at the 4-position of the thiazole ring contribute to its unique chemical properties and biological interactions.

The trifluoromethyl group is a key pharmacophore in modern drug design, known for its ability to modulate metabolic stability, lipophilicity, and binding affinity. Its electron-withdrawing nature enhances the electrophilicity of the adjacent aldehyde group, making it an excellent candidate for further derivatization and functionalization. This feature has been exploited in various synthetic strategies to develop novel bioactive molecules targeting diverse disease pathways.

The thiazole core is a privileged structure in medicinal chemistry, with numerous derivatives exhibiting antimicrobial, anti-inflammatory, anticancer, and antiviral properties. The aldehyde functionality in 2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-4-carbaldehyde serves as a versatile handle for condensation reactions, allowing for the synthesis of Schiff bases, imines, and other heterocyclic compounds. These derivatives have been extensively studied for their potential applications in drug discovery.

Recent advancements in computational chemistry and molecular modeling have highlighted the significance of this compound in virtual screening campaigns. The combination of the trifluoromethyl group and the thiazole scaffold suggests potential interactions with enzymes and receptors involved in metabolic disorders and inflammation. Studies have demonstrated that such structural motifs can enhance binding affinity and reduce off-target effects, making them attractive for developing next-generation therapeutics.

In the context of current research, 2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-4-carbaldehyde has been investigated as a precursor for kinase inhibitors. Thiazole derivatives have shown promise in targeting tyrosine kinases, which are overexpressed in many cancers. The aldehyde group allows for selective functionalization, enabling the design of molecules that can modulate kinase activity without disrupting essential cellular processes. Preliminary studies suggest that derivatives of this compound exhibit inhibitory effects on specific kinases while maintaining high selectivity.

The synthetic accessibility of this compound has also been explored through multi-step organic synthesis. Researchers have developed efficient routes to introduce the trifluoromethyl group via palladium-catalyzed cross-coupling reactions or direct fluorination methods. These synthetic strategies are crucial for large-scale production and further structural optimization.

Moreover, the photophysical properties of 2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-4-carbaldehyde have been studied in detail. The presence of an aldehyde group enhances its fluorescence characteristics, making it a potential candidate for use in bioimaging applications. Fluorescent probes based on thiazole scaffolds have been employed to visualize biological processes in living cells, providing valuable insights into disease mechanisms.

The role of thiazole derivatives in addressing neurological disorders has also gained traction. Research indicates that compounds with similar structural features can interact with neurotransmitter receptors and ion channels, offering potential treatments for conditions such as Alzheimer's disease and epilepsy. The aldehyde functionality allows for further derivatization into amine or ester groups, which can be tailored to enhance solubility and bioavailability.

Environmental considerations have also been taken into account during the development of this compound. Efforts have been made to optimize synthetic pathways to minimize waste generation and reduce hazardous byproducts. Green chemistry principles have been applied to ensure sustainable production practices.

In conclusion,2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-4-carbaldehyde (CAS No. 174006-70-3) represents a promising scaffold with diverse applications in pharmaceutical research. Its unique structural features make it an attractive candidate for further exploration in drug discovery programs targeting various diseases. Continued investigation into its biological activities and synthetic modifications will likely uncover new therapeutic opportunities.

Recommended suppliers
Hunan Well Medicine Synthesis Technology Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Hunan Well Medicine Synthesis Technology Co., Ltd.
Hubei Cuiyuan Biotechnology Co.,Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Hubei Cuiyuan Biotechnology Co.,Ltd
Wuhan Comings Biotechnology Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Wuhan Comings Biotechnology Co., Ltd.
Hebei Liye chemical Co.,Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Hebei Liye chemical Co.,Ltd
SHOCHEM(SHANGHAI) CO.,lTD
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
SHOCHEM(SHANGHAI) CO.,lTD